Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis

M. Opal, Steven; Laterre, Pierre‐François; François, Bruno; P. LaRosa, Steven; C. Angus, Derek; Mira, Jean‐Paul; Wittebole, Xavier; Dugernier, Thierry; Perrotin, D.; Tidswell, Mark; Jáuregui, Luis; Krell, Kenneth; Pachl, Jan; Takahashi, Takeshi; Peckelsen, C.; M. Cordasco, Edward; Chang, Chia-Sheng; Oeyen, Sandra; Aikawa, Naoki; Maruyama, Tatsuya; M.H. Schein, Roland; C. Kalil, André; Van Nuffelen, Marc; Lynn, Melvyn; P. Rossignol, Daniel; Gogate, Jagadish; B. Roberts, Mary; L. Wheeler, Janice; Vincent, Jean‐Louis; the ACCESS Study Group, for

doi:10.1001/jama.2013.2194

Public

Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis

Published in JAMA • Mar 20, 2013

Authors:

Steven M. Opal

Pierre‐François Laterre

Bruno François

Abstract

IMPORTANCE: Eritoran is a synthetic lipid A antagonist that blocks lipopolysaccharide (LPS) from binding at the cell surface MD2-TLR4 receptor. LPS is a major component of the outer membrane of gram-negative bacteria and is a potent activator of the acute inflammatory response. OBJECTIVE: To determi...

Subject

Medicine

Internal medicine

Clinical endpoint

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!